<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="841">
  <stage>Registered</stage>
  <submitdate>18/10/2005</submitdate>
  <approvaldate>28/10/2005</approvaldate>
  <actrnumber>ACTRN12605000694617</actrnumber>
  <trial_identification>
    <studytitle>SCOTROC 4</studytitle>
    <scientifictitle>SCOTROC 4: A Prospective, Multicentre, Randomised Trial of Carboplatin Flat Dosing Vs Intrapatient Dose Escalation in First Line Chemotherapy of Ovarian, Fallopian Tube and Primary Peritoneal Cancers, to improve progression-free survival.</scientifictitle>
    <utrn />
    <trialacronym>SCOTROC 4</trialacronym>
    <secondaryid>National Clinical Trials Registry: NCTR449</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Ovarian, Fallopian Tube and Primary Peritoneal Cancers</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Ovarian and primary peritoneal</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Chemotherapy: Carboplatin given over 6 cycles, 3 weekly.</interventions>
    <comparator>Flat dose (Arm A) or Intra-patient dose escalation (Arm B). The mode of administration is intravenous infusion. Each treatment cycle involves a single dose performed at the start of 3 week periods for a total of 6 cycles. The dose of Carboplatin in both arms for cycle 1 will be dosed to Area Ander Curve (AUC) of 6. Dose escalation in Arm B will be based on the nadir count from the previous cycle. Doses will increase by either 10 or 20% depending on the blood counts.</comparator>
    <control>Dose comparison</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression-free survival</outcome>
      <timepoint>Measured at the time of suspected or clinical progression.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Toxicities</outcome>
      <timepoint>Measured each cycle</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life</outcome>
      <timepoint>Measured each cycle and 2 months post treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical overall response rates and CA125 responses</outcome>
      <timepoint>Measured each cycle and as routine assessments during follow-up</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome> Overall survival</outcome>
      <timepoint>Measured at time of death</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Histologically confirmed epithelial ovarian carcinoma, or primary fallopian tube carcinoma or peritoneal carcinomatosis (ovarian-type), considered unsuitable or unwilling for treatment with platinum-taxane combination therapy; FIGO stages Ic-IV with or without successful cytoreductive surgery at staging laparotomy (Stage Ic patients will be limited to those with malignant cells in ascitic fluid/peritoneal washings, tumour on the surface of the ovary, or pre-operative capsule rupture); Intention to treat patient within 8 weeks of initial surgery. </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>ECOG performance status &gt; 3; Prior treatment with chemotherapy or radiotherapy; Inadequate bone marrow function, renal function or liver function; Concurrent severe and/or uncontrolled co-morbid medical condition; Patients with mixed mesodermal tumours, borderline ovarian tumours or tumours termed "possibly malignant"; Adenocarcinoma of unknown origin, if histologically shown to be mucin-secreting cancer; History of previous malignancy within the previous 5 years or concurrent malignancy (e.g. co-existing endometrial cancer); Pregnant or lactating women; Symptomatic peripheral neuropathy &gt; NCI-CTC grade II.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Centralised web-based randomisation, concealed until interventions are assigned</concealment>
    <sequence>Minimisation technique and Oracle JInitiator software</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>7/11/2005</anticipatedstartdate>
    <actualstartdate>24/01/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate>24/12/2008</actualenddate>
    <samplesize>1300</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC,QLD</recruitmentstate>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Charities/Societies/Foundations</primarysponsortype>
    <primarysponsorname>SGCTG (and also investigator initiated)</primarysponsorname>
    <primarysponsoraddress>Cancer Research United Kingdom
Clinical Trials Unit
Beatson West of Scotland Cancer Centre
1053 Great Western Rd
Glasgow G120YN
United Kingdom</primarysponsoraddress>
    <primarysponsorcountry>United Kingdom</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other Collaborative groups</fundingtype>
      <fundingname>SGCTG</fundingname>
      <fundingaddress>CRUK Clinical Trials Unit
Glasgow</fundingaddress>
      <fundingcountry>United Kingdom</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Cancer Council Australia</fundingname>
      <fundingaddress>Sydney</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>ANZGOG</sponsorname>
      <sponsoraddress>NHMRC Clinical Trials Centre</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>University of Sydney</sponsorname>
      <sponsoraddress>Camperdown</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>SGCTG</sponsorname>
      <sponsoraddress>CRUK Clinical Trials Unit</sponsoraddress>
      <sponsorcountry>United Kingdom</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To assess in a formal protocol whether or not an intrapatient dose-escalation strategy for carboplatin can produce an improved outcome over flat dosing.</summary>
    <trialwebsite />
    <publication>Abstract presentation at ASCO 2009.

Final Publication - Banerjee S, Rustin G, Paul J, Williams C, Pledge S, Gabra H, Skailes G,Lamont A,Hindley A,Goss G, Gilby E, Hogg M, Harper P, Kipps E, Lewsley LA, Hall M, Vasey P, Kaye SB. A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG. Ann Oncol (2013) 24 (3): 679-687</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>University of Sydney</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Central Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Mrs</title>
      <name>Lisa Bailey</name>
      <address>Locked Bag 77
Camperdown NSW 1450</address>
      <phone>+61 2 9562 5000</phone>
      <fax />
      <email>scotroc4@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Dr Geraldine Goss</name>
      <address>Locked Bag 77
Camperdown NSW 1450</address>
      <phone>+61 2 9562 5000</phone>
      <fax />
      <email>scotroc4@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Lisa Bailey</name>
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Geraldine Goss</name>
      <address>ANZGOG Coordinating Centre NHMRC Clinical Trials Centre Locked bag 77 Camperdown NSW 1450</address>
      <phone>+61 2 9562 5000</phone>
      <fax />
      <email>scotroc4@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>